Sangamo Therapeutics

Sangamo lists open positions.

Sangamo offers an internship program.

The page introduces Sangamo Therapeutics' management team, executive leadership team and board of directors.

Nathalie Dubois-Stringfellow, Ph.D., currently serves as Chief Development Officer. She oversees the development and execution of project team strategy for Sangamo’s ZFP therapeutic programs in hemophilia, lysosomal storage disorders, hemoglobinopathies, HIV and Huntington’s disease.

Mr. Jain has served as the Company’s Interim Chief Financial Officer since February 2026, prior to which he served as the Company’s Vice President, Finance and Corporate Controller since September 2021. Earlier in his career, Mr. Jain held roles of increasing responsibility at Deloitte & Touche LLP in both the United States and India. Mr. Jain received a Bachelor of Commerce degree from Mahatma Jyotibha Phule Rohilkhand University in Bareilly, India, and is a Chartered Accountant in India and a

Phillip Ramsey is the Senior Vice President of Technical Operations at Sangamo Therapeutics where he oversees manufacturing, technical development, supply chain and quality.

By translating our groundbreaking science into medicines we aim to transform patients’ lives by replacing today’s symptomatic treatments with tomorrow’s genomic cures.

Sangamo shares announcements and news through its social media channels; inquiries can be sent to info@sangamo.com.

Sangamo uses a multi-platform approach to gene-based therapeutics involving gene therapy, gene editing, cell therapy and gene regulation.

Sangamo's privacy policy explains how it collects, shares and uses personal information.